证券代码：688522 证券简称：纳睿雷达 公告编号：2025-069 号 广东纳睿雷达科技股份有限公司 关于使用部分暂时闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基本情况 | 投资金额 | 不超过 6 亿元 | | --- | --- | | 投资种类 | 安全性高、流动性好的投资产品，包括但不限于协定性存款、结构 | | | 性存款、定期存款、通知存款、大额存单等 | | 资金来源 | 自有资金 | 已履行及拟履行的审议程序 广东纳睿雷达科技股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召开第二届董事会第十二次会议，审议通过了《关于使用部分暂时闲置自有资 金进行现金管理的议案》，同意公司及子公司使用不超过人民币 6 亿元（含）的 暂时闲置自有资金进行现金管理，用于购买安全性高、流动性好的投资产品（包 括但不限于协定性存款、结构性存款、定期存款、通知存款、大额存单等），有 效期自本次董事会审议通过之日起 12 个月内有效，上述额度在期限范围内可循 环 ...

关于 2025 年前三季度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广东纳睿雷达科技股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召开公 司第二届董事会第十二次会议，审议通过了《关于 2025 年前三季度计提资产减值准 备的议案》，该事项无需提交公司股东会审议。现将相关情况公告如下： 一、本次计提资产减值准备情况概述 根据《企业会计准则》及相关会计政策的规定，为客观、公允地反映公司截至 2025 年 9 月 30 日的财务状况及 2025 年前三季度的经营成果，本着谨慎性原则，公司对截 至 2025 年 9 月 30 日公司及子公司的资产进行了减值测试，对可能发生资产减值损失 的相关资产计提减值准备。公司 2025 年前三季度计提各项资产减值准备合计 15,945,240.41 元，具体情况如下表所示： 证券代码：688522 证券简称：纳睿雷达 公告编号：2025-070 号 广东纳睿雷达科技股份有限公司 1 单位：人民币元 | 项目 | 本期发生额 | 备注 | | -- ...

Group 1: A-Share Market Overview - A-shares opened higher on October 24, with the Shanghai Composite Index rising by 0.42%, reaching a peak of 3946.16 points, marking a new high in over ten years [1] - The market turnover reached 1.24 trillion yuan, an increase of over 180 billion yuan compared to the same period of the previous trading day [1] - The technology sector saw collective gains, with commercial aerospace, satellite internet, semiconductors, and memory storage concepts all rising by over 3% [1] Group 2: Zhujiang Piano Stock Performance - Zhujiang Piano (002678) exhibited a "limit-up" and "limit-down" trading pattern, hitting the limit-down within one minute of opening, followed by a rapid rise to limit-up within two minutes [2] - As of the morning close, there were over 750,000 buy orders on Zhujiang Piano, with total buy order funds exceeding 500 million yuan [2] - The company reported a loss of 236 million yuan for 2024 and a loss of 138 million yuan for the first half of this year, indicating recent operational pressure [2][3] Group 3: Commercial Aerospace Sector - The commercial aerospace sector saw significant gains, with the concept index rising by 4.1% on October 24, and several stocks, including Aerospace Zhizhuang and Aerospace Changfeng, hitting the limit-up [4] - Recent advancements in reusable rocket technology were highlighted, with the successful completion of static ignition tests for the Zhuque-3 rocket, which is designed for large satellite constellation networks [4][5] - The commercial aerospace industry is expected to grow significantly, with projections indicating a capacity to produce 100 rockets and 150 commercial satellites annually by 2027 [5] Group 4: Institutional Ratings in Commercial Aerospace - A total of 67 stocks in the A-share market are involved in the commercial aerospace industry, with 16 stocks receiving ratings from five or more institutions [6] - Companies like Feilihua, AVIC Xi'an Aircraft Industry, and Aerospace Electronics are among those with the highest number of institutional ratings [6][7] - Forecasts suggest that these companies are likely to turn profitable or see year-on-year net profit growth by 2025, with some companies expecting profit increases exceeding 100% this year [6][7] Group 5: Northbound Capital Inflows - In the third quarter, 30 stocks in the commercial aerospace sector saw an increase in holdings by northbound funds, with some stocks like Longxi Co. and Zhongtian Rocket experiencing over 100% growth in holdings [8] - Longxi Co. is actively expanding its market presence in civil aviation components, aiming to integrate into the domestic civil aircraft supply chain [8]

Group 1 - China's reusable rocket technology is making significant breakthroughs, with the successful static fire test of the Zhuque-3 rocket, which is designed for large satellite constellation networking [1] - The Zhuque-3 rocket is a large-capacity, low-cost, reusable liquid launch vehicle made from stainless steel, indicating advancements in material use for space technology [1] - The country aims to enhance its reusable rocket capabilities, with multiple rockets, including Zhuque-3 and Tianlong-3, set for maiden flights or tests this year [1] Group 2 - The commercial space industry in China is entering a recovery phase, with a projected increase in rocket launch demand due to the "Hundred Arrows, Thousand Stars" plan, which anticipates nearly 2,500 satellite launches by 2035 [2] - The industry is experiencing a policy boost, with Shandong province aiming for an annual production capacity of 100 rockets and 150 commercial satellites by 2027, targeting a market size of 50 billion yuan [1] Group 3 - A total of 67 stocks in the A-share market are involved in the commercial space industry, with 16 stocks receiving ratings from five or more institutions, indicating strong institutional interest [3] - Companies like Zhimin Da and Narui Radar are expected to see significant profit growth, with projected increases in net profit exceeding 100% for several firms [3][4] - Dragonfly Co. has seen a remarkable increase in northbound capital holdings, with a 1,085.7% increase in shares held, reflecting strong investor interest in the commercial aerospace sector [5][6]

Core Viewpoint - The A-share market experienced a significant rise on October 24, with the Shanghai Composite Index reaching a ten-year high, driven by strong performance in the technology sector and commercial aerospace concepts. Group 1: Market Performance - On October 24, the Shanghai Composite Index rose by 0.42%, peaking at 3946.16 points, marking a new ten-year high [1] - The market's trading volume reached 1.24 trillion yuan, an increase of over 180 billion yuan compared to the previous trading day [1] - The technology sector saw collective gains, with commercial aerospace, satellite internet, semiconductors, and memory storage concepts all rising by over 3% [1] Group 2: Company Specifics - Pearl River Piano - Pearl River Piano (002678) exhibited extreme volatility, opening with a limit down and then quickly reversing to a limit up within two minutes, with over 750,000 buy orders remaining at the limit up price [1] - The stock saw significant trading activity from notable speculators, with Huaxin Securities being a major player in both buying and selling [1] - Pearl River Piano reported a loss of 236 million yuan for 2024 and a loss of 138 million yuan for the first half of the year, indicating ongoing operational challenges [2] Group 3: Commercial Aerospace Sector - The commercial aerospace sector saw a surge, with the concept index rising by 4.1% on October 24, and several stocks reaching their daily limit [1][4] - Recent advancements in reusable rocket technology were highlighted, with the successful testing of the Zhuque-3 rocket, which is designed for large constellation networking [4][5] - The commercial aerospace industry is projected to grow significantly, with a target of producing 100 rockets and 150 commercial satellites annually by 2027, aiming for a market scale of 50 billion yuan [5] Group 4: Institutional Ratings and Predictions - A total of 67 stocks in the A-share market are involved in the commercial aerospace supply chain, with 16 stocks receiving ratings from five or more institutions [6] - Institutions predict that these 16 stocks will achieve profitability or significant net profit growth by 2025, with some companies expecting over 100% growth in net profit this year [6][7] - Notable companies such as Zhimin Da and Narui Radar are expected to see substantial increases in net profit, with growth rates projected at 488.54% and 305.59%, respectively [7]

Core Insights - A total of 123 companies have announced their performance forecasts for the first three quarters, with 96 companies expecting profit increases, representing 78.05% of the total [1] - The overall proportion of companies reporting positive forecasts is 85.37%, with 9 companies expecting profits and 11 and 3 companies forecasting profit declines and losses, respectively [1] - Among the companies expecting profit increases, 44 are projected to have net profit growth exceeding 100%, while 41 companies are expected to see growth between 50% and 100% [1] Company Performance - Xinda Co. is expected to have the highest net profit growth, with a median increase of 3009.81% for the first three quarters [2] - Chuangjiang New Material and Shuo Bei De are projected to have median net profit growth of 2150.09% and 1285.82%, ranking second and third, respectively [2] - The average increase in stock prices for companies expected to double their profits since July is 25.57%, outperforming the Shanghai Composite Index [2] Industry Insights - The sectors with the most companies expecting profit increases include electronics, basic chemicals, and non-ferrous metals, with 10, 7, and 5 companies, respectively [1] - The main board, ChiNext, and STAR Market have 28, 8, and 8 companies, respectively, that are expected to double their profits [1] Stock Performance - Among the stocks, Northern Rare Earth has seen the largest increase since July, with a cumulative rise of 99.80% [2] - In terms of capital flow, the stocks with significant net inflows in the past five days include Shengyi Electronics, Yahua Group, and Guangdong Mingzhu, with net inflows of 189.65 million, 105.79 million, and 66.45 million, respectively [2] - Conversely, Northern Rare Earth, Shenghe Resources, and Chuangjiang New Material experienced significant net outflows, with amounts of 2478.92 million, 881.76 million, and 771.45 million, respectively [2]

Core Viewpoint - The development of radiopharmaceuticals is revolutionizing cancer treatment, allowing targeted delivery of radiation to tumor cells while minimizing damage to surrounding healthy cells [1][2][3]. Industry Overview - Radiopharmaceuticals, which contain radioactive isotopes, are becoming a strategic focus in the biopharmaceutical industry globally, with major pharmaceutical companies entering the field [3][4]. - The global radiopharmaceutical market is projected to grow from $12.6 billion in 2023 to $21 billion by the end of 2029, with a compound annual growth rate (CAGR) of 8.29% from 2024 to 2029 [3]. Clinical Application - The treatment process involves imaging techniques like SPECT or PET to locate tumors and determine the appropriate dosage of radiopharmaceuticals, which are then administered to the patient [5]. - The integration of diagnosis and treatment, referred to as "diagnosis-therapy integration," is a key feature that distinguishes radiopharmaceutical therapy from existing cancer treatment methods [5]. Market Dynamics - The international market has validated the value of radiopharmaceuticals, exemplified by the approval and success of Pluvicto in the U.S. for treating metastatic castration-resistant prostate cancer, generating $271 million in its first year [6]. - In China, as of February 2024, only three innovative radiopharmaceuticals have been approved, highlighting a lag in innovation compared to international counterparts [7][8]. Challenges and Opportunities - The development of innovative radiopharmaceuticals is hindered by the need for collaboration across the supply chain, including the availability of imaging equipment and isotopes [8][9]. - Recent government initiatives aim to enhance the infrastructure for radiopharmaceuticals, including plans for comprehensive coverage of nuclear medicine departments in hospitals by 2025 [10][11]. Innovations and Developments - Companies like Shanghai United Imaging Healthcare have made significant advancements in high-end imaging equipment, contributing to the rapid proliferation of PET technology in China [11]. - Domestic production of isotopes is improving, with companies like China National Nuclear Corporation and Yuan Da Pharmaceutical achieving mass production of various isotopes [12]. Future Outlook - The Chinese radiopharmaceutical industry is expected to enter a phase of accelerated development, with over 205 innovative radiopharmaceuticals currently in clinical stages [12][18]. - Multiple companies, including Fosun Pharma and Baiyang Pharmaceutical Group, are actively expanding their presence in the radiopharmaceutical sector, indicating a robust growth trajectory [14][15][16].

每经记者｜吴泽鹏 每经编辑｜魏官红 曾经资本追逐的风口——低空经济，正在回归理性，直面商业化的残酷考验。10月23日，在广州举行 的"2025国际低空经济贸易博览会（广州）/第八届全球无人系统大会（GUSC2025）"（以下简称广州低 贸会）新闻发布会上，《每日经济新闻》记者了解到，当前，低空经济行业存在资本降温、企业普遍亏 损、模式亟需创新、市场需求不足、商业化瓶颈凸显等情况。 例如，针对资本降温，有行业代表援引数据介绍称，今年上半年，低空经济融资事件与金额分别下降了 15.2%和8%，资本更青睐技术可验证、配套能落地的标的，行业从"泡沫时代"转向理性投资。 需要说明的是，蔡明君提到，当前，政策方面也在加强引导，防止低效竞争。据其介绍，国家发改委已 明确要求防止低空产业低效重复建设，强调硬科技与真实场景结合，推动产业务实发展，避免盲目跟风 和资源浪费。 面对这些情况，即将举办的广州低贸会也在寻求角色转变。它不再满足于作为一个传统的技术"秀场"， 而是试图成为一个"解决方案提供商"。 在此背景下，12月12日至14日将在广州广交会展馆举办的广州低贸会，试图扮演"破局者"角色。展会不 仅展示技术，更首次推出"1 ...

Core Insights - The "2025 International Low Altitude Economic Trade Expo (Guangzhou) / 8th Global Unmanned Systems Conference (GUSC2025)" is scheduled to take place from December 12 to 14, 2025, in Guangzhou, focusing on the theme "Innovate Low Altitude, Service Trade Globally" [1][2] Group 1: Event Overview - The expo will utilize a variety of formats including dynamic and static displays, exhibitions and conferences, as well as indoor and outdoor settings, covering six major topics: meetings, exhibitions, performances, introductions, investments, and trade [1] - The event aims to leverage Guangzhou's position as an international transportation hub and trade gateway, focusing on five core areas: domestic and international low altitude economic policies, industry development trends, core technology innovations, standard alignment, and practical applications [1] Group 2: Highlights and Participation - The expo will feature a 60,000 square meter exhibition area, with 80% of the exhibition space already secured, and is expected to attract over 600 industry chain enterprises and more than 50,000 domestic and international attendees from over 50 countries and regions [3] - Key highlights include over 20 professional forums and seminars, the awarding of the "Golden Wing Award" to set industry benchmarks, and the introduction of an innovative trade service model termed "1+5+N" [2][3] - Notable participating companies include EHang, Xpeng, DJI, and many other leading firms in the low altitude economy sector [3]

Core Viewpoint - Guangdong Narui Radar Technology Co., Ltd. anticipates significant growth in revenue and net profit for the first three quarters of 2025 compared to the same period in 2024, driven by increased customer recognition and a surge in new contracts [2][5]. Performance Forecast - The company expects to achieve approximately 254.02 million yuan in revenue for the first three quarters of 2025, an increase of about 117.82 million yuan, representing a year-on-year growth of approximately 86% [2]. - The projected net profit attributable to the parent company for the same period is around 73.15 million yuan, an increase of about 47.14 million yuan, reflecting a year-on-year increase of approximately 181% [2]. - The net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be about 66.76 million yuan, an increase of approximately 37.10 million yuan, which corresponds to a year-on-year growth of around 125% [2]. Previous Year Performance - In the first three quarters of 2024, the company reported revenue of 136.20 million yuan [4]. - The net profit attributable to the parent company for the same period was 26.01 million yuan [4]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 29.66 million yuan [4]. Reasons for Performance Change - The company's performance improvement is attributed to its product technology and brand advantages, which have led to increased recognition from clients across various sectors. The significant growth in new contracts for hydrological radar and the acceleration of existing orders have contributed to the substantial increase in revenue and enhanced profitability [5].